Eqis Capital Management Inc. reduced its stake in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 38.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,639 shares of the biopharmaceutical company’s stock after selling 20,156 shares during the period. Eqis Capital Management Inc. owned approximately 0.07% of Sucampo Pharmaceuticals worth $332,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of SCMP. Bank of Montreal Can raised its stake in Sucampo Pharmaceuticals by 22.9% in the first quarter. Bank of Montreal Can now owns 24,775 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 4,615 shares during the last quarter. State Street Corp raised its stake in Sucampo Pharmaceuticals by 32.9% in the fourth quarter. State Street Corp now owns 581,835 shares of the biopharmaceutical company’s stock valued at $7,882,000 after buying an additional 143,906 shares during the last quarter. Virginia Retirement Systems ET AL acquired a new stake in Sucampo Pharmaceuticals during the first quarter valued at approximately $536,000. Russell Investments Group Ltd. acquired a new stake in Sucampo Pharmaceuticals during the fourth quarter valued at approximately $555,000. Finally, Adams Diversified Equity Fund Inc. raised its stake in Sucampo Pharmaceuticals by 2.9% in the first quarter. Adams Diversified Equity Fund Inc. now owns 53,400 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 1,500 shares during the last quarter. 56.10% of the stock is currently owned by institutional investors.
Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 11.05 on Wednesday. Sucampo Pharmaceuticals, Inc. has a 1-year low of $9.30 and a 1-year high of $17.55. The stock has a market capitalization of $513.43 million, a price-to-earnings ratio of 18.42 and a beta of 1.46. The stock’s 50 day moving average is $10.44 and its 200 day moving average is $10.82.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.28 by $0.05. The firm had revenue of $56.30 million during the quarter, compared to analysts’ expectations of $54.15 million. Sucampo Pharmaceuticals had a net margin of 11.36% and a return on equity of 43.27%. The firm’s revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.21 EPS. On average, equities analysts forecast that Sucampo Pharmaceuticals, Inc. will post $1.04 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/eqis-capital-management-inc-sells-20156-shares-of-sucampo-pharmaceuticals-inc-nasdaqscmp/1283253.html.
SCMP has been the topic of several recent research reports. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Mizuho reaffirmed a “buy” rating and issued a $14.00 price target on shares of Sucampo Pharmaceuticals in a report on Tuesday, April 4th. Maxim Group reaffirmed a “buy” rating and issued a $21.00 price target on shares of Sucampo Pharmaceuticals in a report on Thursday, April 13th. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, Jefferies Group LLC lowered their price target on shares of Sucampo Pharmaceuticals from $13.00 to $11.00 and set a “hold” rating on the stock in a report on Thursday, May 4th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Sucampo Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $17.00.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.